Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codeine phosphate in sirupus simplex is an oral liquid formulation of the opioid analgesic codeine, being investigated by Universitaire Ziekenhuizen KU Leuven for its effects on esophageal motility. Codeine acts as an agonist at mu-opioid receptors in the central nervous system and the gastrointestinal tract. In the context of esophageal motility research, codeine has been shown to increase resistance at the esophagogastric junction and alter distal esophageal motility patterns. The formulation uses sirupus simplex (simple syrup), a pharmaceutical vehicle consisting of sugar and water, to deliver the active ingredient, codeine phosphate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine phosphate in sirupus simplex.